Evidence map›Paper›PMID 36168121›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells.

Abeer H A Abdelhafiz, Rabah A T Serya, Deena S Lasheen, Nessa Wang, Mansour Sobeh, Michael Wink, Khaled A M Abouzid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abeer H A AbdelhafizPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.ORCID 0000-0002-5994-5995
Rabah A T SeryaPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.ORCID 0000-0002-1349-7269
Deena S LasheenPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.ORCID 0000-0001-7698-9757
Nessa WangInstitute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-7116-5086
Mansour SobehInstitute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-2719-8534
Michael WinkInstitute of Pharmacy and Molecular Biotechnology, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-7875-4510
Khaled A M AbouzidPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.ORCID 0000-0001-9851-5624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) is a leading cause for treatment failure in cancer patients. One of the reasons of MDR is drug efflux by ATP-binding cassette (ABC) transporters in eukaryotic cells especially ABCB1 (P-glycoprotein). In this study, certain novel 1,2,5-trisubstituted benzimidazole derivatives were designed utilising ligand based pharmacophore approach. The designed benzimidazoles were synthesised and evaluated for their cytotoxic activity towards doxorubicin-sensitive cell lines (CCRF/CEM and MCF7), as well as against doxorubicin-resistant cancer cells (CEM/ADR 5000 and Caco-2). In particular, compound

Indexed as

Antineoplastic AgentsNeoplasmsAdenosine TriphosphateATP Binding Cassette Transporter, Subfamily BBenzimidazolesCaco-2 CellsCell Line, TumorCytotoxinsDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmHumansLigandsVerapamilABCB1 protein, humanAdenosine TriphosphateAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BBenzimidazolesCytotoxinsDoxorubicinLigandsVerapamilABCB1 transporterbenzimidazoleligand based pharmacophoremolecular modellingMultidrug resistnce (MDR)

Identifiers

PMID36168121
PMCPMC9543179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.